Substituted quinolone carboxylic acids and potential therapeutic effects in CNS disorders
- The compounds are highly selective for GABA sub A receptor. - The compounds binds to a unique site on GABA sub A receptor.
Treatment of CNS disorders related to the modulation of GRC.
GABA sub A receptor complex (GRC) is ubiquitously expressed throughout the CNS with almost all neurons staining for their presence. It provides majority of the fast inhibitory synaptic transmission regulations. It is well-documented that modulation of the GRC can ameliorate anxiety, seizure activity, and insomnia. However, none of the known drugs are selectively modulate GRC without sides effects. Researchers at UCI invented substituted quinolone carboxylic acids and their derivatives that bind to GRC at a unique site. The compounds can be used potentially to treat and/or prevent a variety of CNS disorders related to abnormal activities of GRC. Such diseases could be acute and chronic pain, depression and bipolar disorder, etc.
7355047
State Of Development The compounds has been tested in animals studies. Tech ID/UC Case 24922/2002-440-0 Related Cases 2002-440-0
美國
